Company intelligence / Profile preview

Kowa

Nagoya, Aichi, Japan

Ownership: Private
Employees: ~8074
Development stage: Other

Overview

Kowa has several commercialized therapies in the cardiovascular/metabolic space, including statins and other lipid-lowering agents; it is active in both clinical development and commercialization internationally, with a long-standing track record and presence in global cardiovascular and metabolic disease R&D and marketed products[5][6][7].

Therapeutic areas: ImmunologyCardiovascularOphthalmologyEndocrinologyNeurologyDermatologyOncology
Modalities: Small moleculeBiologicDevice
Industry: Pharma

Partnerships

Nicox S.A. (for NCX 470 licensing)[5]Brigham and Women’s Hospital, Harvard University (Center for Interdisciplinary Cardiovascular Sciences CICS)[5][7]

Beyond the preview

Go deeper on Kowa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kowa.

Explore the full profile